Valuation: Tarsus Pharmaceuticals, Inc.

Market Cap 344.96Cr 306.4Cr 286.53Cr 261.11Cr 491.58Cr 33TCr 498.34Cr 3.47TCr 1.34TCr 17TCr 1.3TCr 1.27TCr 54TCr P/E 2026 *
-16.2x
P/E 2027 * 1,025x
Enterprise Value 311.34Cr 276.53Cr 258.6Cr 235.66Cr 443.66Cr 30TCr 449.76Cr 3.13TCr 1.21TCr 15TCr 1.17TCr 1.14TCr 49TCr EV / Sales 2026 *
4.32x
EV / Sales 2027 * 3.21x
Free-Float
97.31%
Yield 2026 *
-
Yield 2027 * -
1 day-3.59%
1 week-0.62%
Current month-3.97%
1 month+1.94%
3 months+23.98%
6 months+7.50%
Current year-7.80%
1 week 73.85
Extreme 73.8501
79.1
1 month 73.85
Extreme 73.8501
91.53
Current year 53.89
Extreme 53.89
91.53
1 year 53.89
Extreme 53.89
91.53
3 years 12.57
Extreme 12.57
91.53
5 years 10.8
Extreme 10.8001
91.53
10 years 10.8
Extreme 10.8001
91.53
Manager TitleAgeSince
Chief Executive Officer 48 01/09/2018
Director of Finance/CFO 64 24/04/2023
Chief Tech/Sci/R&D Officer 47 04/11/2024
Director TitleAgeSince
Chairman 48 02/12/2022
Director/Board Member 71 01/12/2019
Director/Board Member 80 01/01/2017
Date Insider Type Main position Quantity % Market Cap. Importance
15/09/26 Exercice

Director

604 0.0014%
15/09/26 Exercice

Director

12,902 0.0294%
15/09/26 Exercice

Director

402 0.0009%
Change 5-day change 1-year change 3-year change Capi.($)
-3.59%-0.62%+31.65%+332.86% 344.96Cr
-0.26%-2.24%+39.98%+114.65% 1,03100Cr
-2.09%-4.11%+39.51%+67.30% 64TCr
-0.48%-1.83%+6.51%+75.57% 46TCr
-1.33%-2.79%+59.60%+40.27% 36TCr
-0.03%-3.96%+23.63%+40.70% 33TCr
-1.58%-0.76%+13.50%+26.44% 27TCr
-2.02%-2.97%-3.25%+9.88% 25TCr
-2.75%+1.14%+37.58%+54.21% 23TCr
-1.13%-1.32%+32.89%+99.34% 18TCr
Average -1.55%+0.25%+28.16%+86.12% 37.67TCr
Weighted average by Cap. -1.12%-0.34%+30.88%+70.54%

Financials

2026 *2027 *
Net sales 72Cr 64Cr 60Cr 55Cr 102.75Cr 6.94TCr 104.16Cr 724.55Cr 280.48Cr 3.54TCr 270.72Cr 264.85Cr 11TCr 93Cr 82Cr 77Cr 70Cr 132.13Cr 8.93TCr 133.95Cr 931.74Cr 360.69Cr 4.55TCr 348.13Cr 340.59Cr 15TCr
Net income -22Cr -19Cr -18Cr -17Cr -31Cr -2.1TCr -32Cr -219.52Cr -85Cr -1.07TCr -82Cr -80Cr -3.44TCr 68.98L 61.27L 57.3L 52.21L 98.3L 66Cr 99.65L 6.93Cr 2.68Cr 34Cr 2.59Cr 2.53Cr 108.64Cr
Net Debt -34Cr -30Cr -28Cr -25Cr -48Cr -3.24TCr -49Cr -337.89Cr -130.8Cr -1.65TCr -126.25Cr -123.51Cr -5.3TCr -48Cr -42Cr -40Cr -36Cr -68Cr -4.58TCr -69Cr -477.94Cr -185.02Cr -2.33TCr -178.58Cr -174.7Cr -7.49TCr
Logo Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company's lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. It is investigating the development of its product candidates to address targeted diseases with medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction. It is also developing IRX-101, an investigational ocular antiseptic.
Employees
370
Date Price Change Volume
02/26/02 $75.64 -3.78% 4,88,025
30/26/30 $78.61 +2.50% 15,62,882
29/26/29 $76.69 -0.16% 4,17,966
28/26/28 $76.81 +1.48% 13,09,604
25/26/25 $75.69 -0.36% 7,21,440
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
78.61USD
Average target price
99.50USD
Spread / Average Target
+26.57%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TARS Stock